MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells

Table 1

Clinical Characteristics of AML Patients.

Characteristics	Median (range)	No. of cases
Sex
Female		4
Male		8
Total		12
Age
Median (years)	56.5 (27-76)
WBC
Median (×10^9/L)	15.15 (1.25-221.0)
Platelets
Median (×10^9/L)	71.5 (13.0-247.0)
AML FAB subtype
AML with maturation: M2		7
Acute monoblastic or monocytic leukemia: M5		5
Karyotype
Normal		6
Medium		2
Complex		2
Unknown		2
Gene mutations
NPM1		4
FLT3-ITD		4
TP53		2
RUNX1		1
CEBPA		1

Abbreviations: AML: acute myeloid leukemia; WBC: white blood cell; FAB subtype: French-American-British subtype; NPM1: nucleophosmin 1; FLT3-ITD: FLT3 internal tandem duplication; TP53: tumor protein p53; RUNX1: runt-related transcription factor 1; CEBPA: CCAAT enhancer binding protein alpha.